Synthesis and Activity Evaluation of Nasopharyngeal Carcinoma Inhibitors Based on 6‐(Pyrimidin‐4‐yl)‐1H‐indazole

Human nasopharyngeal carcinoma is a common head and neck malignancy with high incidence in Southeast Asia and Southern China. It is necessary to develop safe, effective and inexpensive anticancer agents to improve the therapeutics of patients with nasopharyngeal carcinoma. A series of small molecular compounds based on 6‐(pyrimidin‐4‐yl)‐1H‐indazole were synthesized and evaluated for antiproliferative activities against human nasopharyngeal carcinoma cell lines SUNE1. Compounds 6b, 6c, 6e and 6l showed potent antiproliferative activities similar to positive control drug cisplatin in vitro with lower nephrotoxicity than it. N‐[4‐(1H‐Indazol‐6‐yl)pyrimidin‐2‐yl]benzene‐1,3‐diamine (6l) was selected for further study. It was found that 6l induced mitochondria‐mediated apoptosis and G2/M phase arrest in SUNE1 cells. Furthermore, compound 6l at 10 mg/kg can suppress the growth of an implanted SUNE1 xenograft with a TGI% (tumor growth inhibition) value of 50 % and did not cause serious side effects in BALB/c nude mice. This study suggests that 6‐(pyrimidin‐4‐yl)‐1H‐indazole derivatives are a series of small molecule compounds with anti‐nasopharyngeal carcinoma activities.

[1]  G. Balogh,et al.  Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors. , 2018, Bioorganic & medicinal chemistry.

[2]  Chang Kai Soh,et al.  Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma. , 2018, Journal of medicinal chemistry.

[3]  D. Bearss,et al.  Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors. , 2017, Bioorganic & medicinal chemistry letters.

[4]  M. Taniwaki,et al.  Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma. , 2017, Experimental hematology.

[5]  Ying Sun,et al.  Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors. , 2017, European journal of medicinal chemistry.

[6]  Jian Ding,et al.  Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. , 2017, European journal of medicinal chemistry.

[7]  Huibin Zhang,et al.  Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents. , 2017, European journal of medicinal chemistry.

[8]  Q. You,et al.  2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. , 2017, European journal of medicinal chemistry.

[9]  M. Shen,et al.  Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents. , 2017, European journal of medicinal chemistry.

[10]  Yingxia Li,et al.  Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors. , 2017, Bioorganic & medicinal chemistry letters.

[11]  Deyong Ye,et al.  The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer. , 2017, European journal of medicinal chemistry.

[12]  S. Liang,et al.  Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy , 2017, BMC Cancer.

[13]  Jianxin Yu,et al.  Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization. , 2017, European journal of medicinal chemistry.

[14]  W. Qian,et al.  PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242 , 2017, Oncotarget.

[15]  C. Schultz-Fademrecht,et al.  Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. , 2017, Journal of medicinal chemistry.

[16]  Narendra Kumar Patel,et al.  Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy. , 2016, Bioorganic & medicinal chemistry letters.

[17]  A. Budrukkar,et al.  Outcomes in nasopharyngeal carcinoma: Results from a nonendemic cohort. , 2016, Indian journal of cancer.

[18]  W. Xue,et al.  Global trends in incidence and mortality of nasopharyngeal carcinoma. , 2016, Cancer letters.

[19]  Xiaoyan Pan,et al.  Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine. , 2015, European journal of medicinal chemistry.

[20]  Narendra Kumar Patel,et al.  The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents. , 2015, Journal of medicinal chemistry.

[21]  Narendra Kumar Patel,et al.  The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents. , 2015, Journal of medicinal chemistry.

[22]  D. Kwong,et al.  Multigene pathway‐based analyses identify nasopharyngeal carcinoma risk associations for cumulative adverse effects of TERT‐CLPTM1L and DNA double‐strand breaks repair , 2014, International journal of cancer.

[23]  L. Deady,et al.  Synthesis and biological evaluation of 2-anilino-4-substituted-7H-pyrrolopyrimidines as PDK1 inhibitors. , 2014, Bioorganic & medicinal chemistry.

[24]  H. M. Petrassi,et al.  Discovery, optimization, and biological evaluation of 5-(2-(trifluoromethyl)phenyl)indazoles as a novel class of transient receptor potential A1 (TRPA1) antagonists. , 2014, Journal of medicinal chemistry.

[25]  M. Sathiyendiran,et al.  Microwave synthesis, characterization and bio-efficacy evaluation of novel chalcone based 6-carbethoxy-2-cyclohexen-1-one and 2H-indazol-3-ol derivatives. , 2013, European journal of medicinal chemistry.

[26]  S. Rault,et al.  New hypotheses for the binding mode of 4- and 7-substituted indazoles in the active site of neuronal nitric oxide synthase. , 2012, Bioorganic & medicinal chemistry.

[27]  Anupam Verma,et al.  Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. , 2011, ACS medicinal chemistry letters.

[28]  S. Rabindran,et al.  Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. , 2011, Journal of medicinal chemistry.

[29]  Ayaz Najafov,et al.  Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. , 2011, The Biochemical journal.

[30]  J. Briand,et al.  Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery. , 2010, ACS medicinal chemistry letters.

[31]  P. Lograsso,et al.  Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. , 2010, Journal of medicinal chemistry.

[32]  S. Rault,et al.  Protected Indazole Boronic Acid Pinacolyl Esters: Facile Syntheses and Studies of Reactivities in Suzuki—Miyaura Cross‐Coupling and Hydroxydeboronation Reactions. , 2009 .

[33]  Feng Jiang,et al.  Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer , 2009, Molecular Cancer Research.

[34]  S. Rault,et al.  Protected Indazole Boronic Acid Pinacolyl Esters: Facile Syntheses and Studies of Reactivities in Suzuki-Miyaura Cross-Coupling and Hydroxydeboronation Reactions , 2009 .

[35]  A. Schmidt,et al.  Recent Advances in the Chemistry of Indazoles , 2008 .

[36]  V. Arán,et al.  Pharmacological properties of indazole derivatives: recent developments. , 2005, Mini reviews in medicinal chemistry.